Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Becton, Dickinson and Company. (5/18/21). "Press Release: BD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain to Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business". Madrid.

Region Region Zaragoza
  Country Spain (Espańa)
Organisations Organisation Becton, Dickinson (Group)
  Organisation 2 Becton, Dickinson & Co. (NYSE: BDX)
  Group Becton, Dickinson (Group)
Products Product contract manufacturing (drugs)
  Product 2 injectional drug delivery technology
     


New plant will produce drug delivery devices, employ 150 people in 2024 and up to 600 when full operations start in 2030


BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain, that will create up to 600 jobs by 2030.

BD plans to begin construction of the new plant in late 2021, and the new facility will be the fourth manufacturing plant for BD in Spain. The site will initially have a workforce of 150 people and encompass an area of 8,000 square meters (86,000 square feet). By 2030 it is expected to employ up to 600 people with an area of 30,000 square meters (323,000 square feet). The new facility will meet high sustainability and eco-efficiency standards, and it will be a fully digital site, incorporating the latest in intelligent and autonomous technologies, also knowns as Industry 4.0 solutions.

"BD's new plant in Zaragoza will produce drug delivery devices, primarily for pharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs," said Eric Borin, worldwide president of BD Pharmaceutical Systems. "This new plant will also add needed capacity to support major vaccination campaigns, such as the one currently taking place in response to the COVID-19 pandemic."

The new site represents a portion of the $1.2 billion USD investment over four years that was announced in December 2020 to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) as part of BD's 2025 growth strategy. The new site also continues BD's commitment to Spain, where it started operations more than 40 years ago and currently has three production plants located in San Agustín de Guadalix, Fraga and Almaraz. These facilities produce a total of 10 billion medical devices each year and employ 1,500 people. The Fraga plant is a key production site for the manufacture of COVID-19 vaccination injection devices.

"After the December 2020 announcement of BD's intention to build a new plant in Europe, a detailed site location search process resulted in Zaragoza, Aragon being selected because of the optimal conditions offered by the region, the synergies that could be produced with BD's Fraga facility, and the results and excellent performance of the plants that currently exist in Spain," Lourdes López, general director of BD in Spain and Portugal, added.

The planned site in Zaragoza is subject to administration process completion.


About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.


Contacts:

Media:
Troy Kirkpatrick
VP, Public Relations
858.617.2361
troy.kirkpatrick@bd.com

Investors:
Kristen M. Stewart, CFA
SVP, Strategy & Investor Relations
201.847.5378
kristen.stewart@bd.com

   
Record changed: 2021-06-11

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Becton, Dickinson (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top